View : 155 Download: 0
Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters
- Title
- Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters
- Authors
- Park; Sang-In; Sohyun; Lee; Kunse; Kwak; Hye Won; Kim; Yong Kwan; Hyeong-Jun; Bang; Yoo-Jin; Jae-Yong; Daegeun; Seo; Ki-Weon; Su Jeen; Hun; Yeonhwa; Do-Hyung; Hyo-Jung; Jung; Seo-Yeon; Ga; Eulhae; Hwang; Jaehyun; Na; Woonsung; Hong; So-Hee; Sang-Myeong; Nam; Jae-Hwan
- Ewha Authors
- 홍소희
- SCOPUS Author ID
- 홍소희
- Issue Date
- 2024
- Journal Title
- Vaccine
- ISSN
- 0264-410X
- Citation
- Vaccine vol. 42, no. 2, pp. 69 - 74
- Keywords
- Intranasal vaccination; Measles virus vector; Messenger RNA; SARS-CoV-2
- Publisher
- Elsevier Ltd
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Background: As the nasal mucosa is the initial site of infection for COVID-19, intranasal vaccines are more favorable than conventional vaccines. In recent clinical studies, intranasal immunization has been shown to generate higher neutralizing antibodies; however, there is a lack of evidence on sterilizing immunity in the upper airway. Previously, we developed a recombinant measles virus encoding the spike protein of SARS-CoV-2 (rMeV-S), eliciting humoral and cellular immune responses against SARS-CoV-2. Objectives: In this study, we aim to provide an experiment on nasal vaccines focusing on a measles virus platform as well as injection routes. Study design: Recombinant measles viruses expressing rMeV-S were prepared, and 5 × 105 PFUs of rMeV-S were administered to Syrian golden hamsters via intramuscular or intranasal injection. Subsequently, the hamsters were challenged with inoculations of 1 × 105 PFUs of SARS-CoV-2 and euthanized 4 days post-infection. Neutralizing antibodies and RBD-specific IgG in the serum and RBD-specific IgA in the bronchoalveolar lavage fluid (BALF) were measured, and SARS-CoV-2 clearance capacity was determined via quantitative reverse-transcription PCR (qRT-PCR) analysis and viral titer measurement in the upper respiratory tract and lungs. Immunohistochemistry and histopathological examinations of lung samples from experimental hamsters were conducted. Results: The intranasal immunization of rMeV-S elicits protective immune responses and alleviates virus-induced pathophysiology, such as body weight reduction and lung weight increase in hamsters. Furthermore, lung immunohistochemistry demonstrated that intranasal rMeV-S immunization induces effective SARS-CoV-2 clearance that correlates with viral RNA content, as determined by qRT-PCR, in the lung and nasal wash samples, SARS-CoV-2 viral titers in lung, nasal wash, BALF samples, serum RBD-specific IgG concentration, and RBD-specific IgA concentration in the BALF. Conclusion: An intranasal vaccine based on the measles virus platform is a promising strategy owing to the typical route of infection of the virus, the ease of administration of the vaccine, and the strong immune response it elicits. © 2023 Elsevier Ltd
- DOI
- 10.1016/j.vaccine.2023.12.011
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML